By: Benzinga
UPDATE: Wedbush Securities Initiates Regulus Therapeutics at Outperform on Pipeline Progress
Wedbush Securities initiated coverage on Regulus Therapeutics (NASDAQ: RGLS ) with an Outperform rating and a $10 price target. Wedbush Securities noted, "Regulus is developing oligonucleotide drugs that target microRNA, important regulators of gene expression whose dysregulation is implicated in a variety of diseases and disease states.
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here